CORT — Corcept Therapeutics Incorporated

Summary of Corcept Therapeutics Q4 2025 Earnings Call

1. Key Financial Results and Metrics

• Revenue: Corcept reported $761 million in revenue for 2025, up from $675 million in 2024.
• Net Income: Net income decreased to $99.7 million from $141.2 million year-over-year.
• Cash and Investments: As of December 31, 2025, cash and investments totaled $532 million, reflecting a $245 million stock repurchase program.
• 2026 Revenue Guidance: The company expects revenue to grow to between $900 million and $1 billion.

2. Strategic Updates and Business Highlights

• Cushing's Syndrome Business: The demand surged, with a record number of new prescriptions and patients. A transition to a new specialty pharmacy is expected to enhance capacity and service.
• Clinical Trials: Positive results from the ROSELLA trial in platinum-resistant ovarian cancer were highlighted, showing improved overall survival and progression-free survival.
• Catalyst Trial: The CATALYST trial demonstrated that a significant portion of patients with uncontrolled diabetes had hypercortisolism, indicating a broader market for treatment.
• Pipeline Development: The company is advancing multiple studies, including those for relacorilant in oncology and other conditions like metabolic dysfunction-associated steatohepatitis (MASH) and ALS.

3. Forward Guidance and Outlook

• Cushing's Syndrome Growth: The Cushing's syndrome business is projected to reach at least $2 billion in annual revenue by the end of the decade, with further acceleration expected upon relacorilant's approval.
• FDA Engagement: Corcept plans to meet with the FDA in April to discuss the complete response letter (CRL) regarding relacorilant and explore options for resubmission or further studies.

4. Bad News, Challenges, or Points of Concern

• FDA CRL: The FDA did not approve relacorilant for Cushing's syndrome, citing concerns that the company believes are unfounded. Corcept plans to appeal this decision.
• Supply Chain Issues: Transitioning to a new pharmacy vendor caused temporary disruptions in service and capacity, although improvements are now being seen.
• Net Income Decline: The decrease in net income raises concerns about profitability amidst rising operational costs and competitive pressures.

5. Notable Q&A Insights

• FDA Communication: Management expressed frustration over the FDA's decision-making process and indicated a significant gap between their interpretation of the data and the FDA's concerns.
• Pricing Strategy: The average gross-to-net discount for Korlym is about 30%, with expectations of slight increases in discounts in 2026.
• Future Trials: There is consideration for conducting additional randomized trials for relacorilant in type 2 diabetes and hypertension, depending on FDA feedback.
• Competitive Landscape: The introduction of KEYTRUDA in ovarian cancer treatment was discussed, with management emphasizing the unique advantages of their therapy and its potential for broad adoption.

Overall, while Corcept Therapeutics demonstrated strong revenue growth and positive clinical trial results, challenges related to FDA approvals and operational disruptions pose significant risks to its future performance.